AOD-9604 vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | Setmelanotide |
|---|---|---|
| Dose Range | 300 mcg–500 mcg | 1 mg–3 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 12–24 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |
What They Have in Common
AOD-9604, Setmelanotide are both commonly used for:
Which Has Stronger Evidence?
- Fat Loss: Setmelanotide has stronger research support.
| Goal | AOD-9604 | Setmelanotide |
|---|---|---|
| Fat Loss | medium | high |
Key Studies
AOD-9604
- AOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis, 2013
- AOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000), 2004
Setmelanotide
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.), 2026
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine, 2026
- Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism, 2026
Ready to Learn More?
Looking for trusted sources?